Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5395547 | 0.90 | ALDH1A1 (0.56) | KMT2AMEN1SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL10967640 | 0.90 | LMNA (0.55) | KMT2AMEN1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL546987 | 0.90 | MEN1 (0.49) | KMT2AMEN1SIGMAR1KDM4E | |
| SCHEMBL13962874 | 0.88 | SIGMAR1 (0.54) | KMT2AMEN1SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL13962841 | 0.87 | CHRM2 (0.51) | KMT2AMEN1SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL13962938 | 0.85 | MEN1 (0.56) | KMT2AMEN1ALDH1A1KDM4ELMNA | |
| SCHEMBL13962943 | 0.84 | MEN1 (0.46) | KMT2AMEN1SIGMAR1ALDH1A1KCNA3 | |
| SCHEMBL2079886 | 0.83 | CHRNB2 (0.42) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13962854 | 0.82 | MEN1 (0.55) | KMT2AMEN1ALDH1A1OPRM1LMNA | |
| SCHEMBL10967944 | 0.81 | HTT (0.54) | KMT2AMEN1SIGMAR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274572-B1 | NOVEL INHIBITORS OF AUTOTAXIN | ZYDUS LIFESCIENCES LTD (IN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4599849-A2 | NOVEL INHIBITORS OF AUTOTAXIN | Zydus Lifesciences Limited (IN) | 2025-08-13 | — | — | EP | disclosed |
| US-20240327407-A1 | NOVEL INHIBITORS OF AUTOTAXIN | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-10-03 | — | — | US | disclosed |
| EP-4274572-A1 | NOVEL INHIBITORS OF AUTOTAXIN | Zydus Lifesciences Limited (IN) | 2023-11-15 | — | — | EP | disclosed |
| CN-116806150-A | Novel autotaxin inhibitors | 载度思生命科学有限公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2022149010-A1 | NOVEL INHIBITORS OF AUTOTAXIN | CADILA HEALTHCARE LIMITED (IN) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022149010-A1 | NOVEL INHIBITORS OF AUTOTAXIN | CADILA HEALTHCARE LIMITED (IN) | 2022-07-14 | — | — | WO | disclosed |
| CN-109415337-B | Piperidine as multiple endocrine adenoma protein inhibitor | 密执安大学评议会 | 2022-01-18 | — | — | CN | disclosed |
| EP-3452461-B1 | PIPERIDINES AS MENIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210198237-A1 | PIPERIDINES AS MENIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-07-01 | — | — | US | disclosed |
| US-10899738-B2 | Piperidines as menin inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-01-26 | — | — | US | disclosed |
| US-20190152947-A1 | PIPERIDINES AS MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-23 | — | — | US | disclosed |
| EP-3452461-A1 | PIPERIDINES AS MENIN INHIBITORS | The Regents Of The University Of Michigan Office Of Technology Transfer (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017192543-A1 | PIPERIDINES AS MENIN INHIBITORS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-1292596-B1 | 1,3,8-TRIAZA-SPIRO¬4,5 DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | EP | disclosed |
| EP-1292596-A1 | 1,3,8-TRIAZA-SPIRO[4,5]DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-19 | — | — | EP | disclosed |
| US-6482829-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020006932-A1 | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-17 | — | — | US | disclosed |
| WO-2001094346-A1 | 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198237-A1 | PIPERIDINES AS MENIN INHIBITORS | MEN1, WFS1, BRCA1 | KMT2A 977/4885MEN1 1/4885SIGMAR1 2654/4885 |
| US-10899738-B2 | Piperidines as menin inhibitors | MEN1, GDI2, GNAQ | KMT2A 1040/4885MEN1 1/4885SIGMAR1 2667/4885 |
| US-20190152947-A1 | PIPERIDINES AS MENIN INHIBITORS | MEN1, GDI2, GNAQ | KMT2A 1040/4885MEN1 1/4885SIGMAR1 2667/4885 |
| US-20020006932-A1 | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor | TACR1, TACR2, NPR1 | KMT2A 1934/4885MEN1 973/4885SIGMAR1 13/4885 |
| US-20240327407-A1 | NOVEL INHIBITORS OF AUTOTAXIN | ENPP2, ATXN10, SPINT2 | KMT2A 1997/4885MEN1 1526/4885SIGMAR1 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.